 Wyeth undertook a Phase 1 and 2 clinical trial in 2005 and 2006 of stamulumab.The multiple ascending dose trial (36 patients per cohort) contained some measures of efficacy.The trial's participants included people afflicted with Facioscapulohumeral muscular dystrophy, Becker's muscular dystrophy, and Limb-girdle muscular dystrophy.